Biomind Labs Inc. BMNDF
0.25 USD 0.00 (+0.00%)
At closeNov 10, 2026, 4:00 PM EST
0.2502 Day range 0.2502
0.011 52-week range 0.80
- YTD
- +119.47%
- 1 year
- +1,483.54%
News
accessnewswire.com Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada VANCOUVER, BC / ACCESS Newswire / August 6, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND) (OTC PINK:BMNDF), a clinical-stage biopharmaceutical company focused on transforming…
accessnewswire.com Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States A defining moment for the future of mental health, and for Biomind's mission to transform neuropsychiatric care through next-generation psychedelic medicines TORONTO, ON / ACCESS Newswire / April 20,…
accessnewswire.com Biomind Labs Announces CAD $2.52 Million Private Placement Financing NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / January 27, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC…
accessnewswire.com Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood BIOMIND LABS ACCELERATES FDA PATHWAY FOR 5-MEO-DMT CANDIDATE BMND08 AND GRANTS STOCK OPTIONS TORONTO, ON / ACCESS Newswire / December 3, 2025 / Biomind Labs Inc. ("Biomind" or the "Company")…
accessnewswire.com Biomind Labs Announces Revocation of Cease Trade Order TORONTO, ON / ACCESS Newswire / November 25, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that the Ontario Securities Commission (the "Commission") has…
accessnewswire.com Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board TORONTO, ON / ACCESS Newswire / November 18, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that it has filed the following continuous disclosure documents…
accesswire.com Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies TORONTO, ON / ACCESSWIRE / November 20, 2024 / Biomind Labs Inc. (" Biomind " or the " Company ") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI) , a leading biotech company at the forefront of…
accesswire.com Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways TORONTO, ON / ACCESSWIRE / July 18, 2024 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI), a leading biotech company dedicated to developing the next-generation…
businesswire.com Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression & Anxiety in Alzheimer's Disease TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to…
businesswire.com Biomind Labs Provides Corporate Update TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of…
businesswire.com Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of…
benzinga.com GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today GAINERS: GH Research (NASDAQ: GHRS) shares closed up 6.63% at $11.74